|Bid||195.91 x 200|
|Ask||200.63 x 1800|
|Day's Range||196.79 - 199.30|
|52 Week Range||156.37 - 201.80|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.24%|
MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.
Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.
ADP, a human capital management solution provider, releases a monthly report on US non-farm employment. This monthly report is prepared by using actual anonymous payroll data of 411,000 clients that ADP services. The report is released two days before the non-farm payrolls data, so this report prepares markets for any surprises in the jobs report.
Radius Health (RDUS) is a biopharmaceutical company that has recently turned into a commercial stage healthcare company. Of the seven analysts covering Radius Health in January 2018, three have given the stock “buy” or higher ratings, while four have given it “hold” ratings. The mean rating for the stock is 2.43, and it has a target price of $47.5.
A potential problem for value investors that favor index funds in the months ahead: Value indexes are loaded to the gills with competing holdings that are likely to offset each other.
Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.
How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.
As per the ADP National Employment Report, US private sector employment rose by 250,000 jobs in December, a healthy improvement from the 190,000 jobs added in November.
The legislative move has led to the return of Trump trade and investors are cashing in on the opportunity with ETFs that are deemed to gain most on tax reforms.
In a recent post by Project Syndicate, Nobel laureate and Yale economics professor Robert Shiller said that stock markets (SPY) are dangerously close to a bear market. Professor Shiller’s cyclically adjusted…...
Key U.S. stock indexes were slightly higher Tuesday as Apple rose but some other big-cap techs gave up early gains.
Key U.S. stock indexes were lower in the stock market today as Apple and other techs fell under pressure.
Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...
With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).
Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.
In 1Q17, the Advisory Board (ABCO) reported revenues of ~$194.1 million, which was higher than its guidance of $185 million–$190 million but ~0.7% lower YoY.
According to Reuters, on June 30, 2017, all of the sell-side analysts tracking Flotek Industries (FTK) have rated the stock a “buy” or some equivalent.
A large-cap blend ETF led U.S. diversified funds in June, but small-cap names dominated the rest of the list.
As of June 20, 2017, Papa John’s was trading at a forward PE multiple of 24.8x—compared to 27.3x before the announcement of its 1Q17 earnings.